TET2 repression by androgen hormone regulates global hydroxymethylation status and prostate cancer progression

Nature Communications

Volumn 6, Issue , 2015, Pages

  Takayama, Ken Ichi ^a   Misawa, Aya ^a   Suzuki, Takashi ^b   Takagi, Kiyoshi ^b   Hayashizaki, Yoshihide ^c,d   Fujimura, Tetsuya ^a   Homma, Yukio ^a   Takahashi, Satoru ^e   Urano, Tomohiko ^a   Inoue, Satoshi ^a,f  

^a UNIVERSITY OF TOKYO   (Japan)

^b TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c RIKEN YOKOHAMA INSTITUTE   (Japan)

^d RIKEN   (Japan)

^e NIHON UNIVERSITY   (Japan)

^f SAITAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; MICRORNA 125B; MICRORNA 200A; MICRORNA 22; MICRORNA 29; MICRORNA 29A; MICRORNA 29B; MICRORNA 30A; PROTEIN; TET2 PROTEIN; UNCLASSIFIED DRUG; 5-HYDROXYMETHYLCYTOSINE; ANDROGEN RECEPTOR; CYTOSINE; DNA BINDING PROTEIN; FOXA1 PROTEIN, HUMAN; HEPATOCYTE NUCLEAR FACTOR 3ALPHA; MESSENGER RNA; MICRORNA; MIRN29 MICRORNA, HUMAN; ONCOPROTEIN; TARGET OF RAPAMYCIN KINASE; TET2 PROTEIN, HUMAN;

AMINO ACID; ANDROGEN; CANCER; CATALYSIS; GENE EXPRESSION; HORMONE; METHYLATION; OXIDATION; PROTEIN; TUMOR;

ADULT; AGED; ARTICLE; CANCER CELL; CANCER GROWTH; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; DNA METHYLATION; DNA MODIFICATION; GENE REPRESSION; GLEASON SCORE; HISTONE MODIFICATION; HUMAN; HUMAN CELL; MALE; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; RNA SEQUENCE; SIGNAL TRANSDUCTION; ANALOGS AND DERIVATIVES; ANIMAL; BAGG ALBINO MOUSE; CANCER TRANSPLANTATION; CHROMATIN IMMUNOPRECIPITATION; DISEASE COURSE; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETICS; HEK293 CELL LINE; HYDROXYLATION; IMMUNOHISTOCHEMISTRY; METABOLISM; MIDDLE AGED; PROSTATE TUMOR; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS; TUMOR CELL LINE; WESTERN BLOTTING;

ANIMALIA;

AGED; ANDROGENS; ANIMALS; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL PROLIFERATION; CHROMATIN IMMUNOPRECIPITATION; CYTOSINE; DISEASE PROGRESSION; DNA METHYLATION; DNA-BINDING PROTEINS; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HEK293 CELLS; HEPATOCYTE NUCLEAR FACTOR 3-ALPHA; HUMANS; HYDROXYLATION; IMMUNOHISTOCHEMISTRY; MALE; MICE, INBRED BALB C; MICRORNAS; MIDDLE AGED; NEOPLASM TRANSPLANTATION; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS; RECEPTORS, ANDROGEN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SEQUENCE ANALYSIS, RNA; TOR SERINE-THREONINE KINASES;

EID: 84942694022     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms9219     Document Type: Article

References (56)

1. Suganuma, T., Workman, J. L. Chromatin and signaling. Curr. Opin. Cell Biol. 25, 322-326 (2013).
2. Wu, H., Zhang, Y. Reversing DNA methylation: mechanisms, genomics, and biological functions. Cell 156, 45-68 (2014).
3. Wu, H., Zhang, Y. Mechanisms and functions of Tet protein-mediated 5-methylcytosine oxidation. Genes Dev. 25, 2436-2452 (2011).
4. Kohli, R. M., Zhang, Y. TET enzymes, TDG and the dynamics of DNA demethylation. Nature 502, 472-479 (2013).
5. Solary, E., Bernard, O. A., Tefferi, A., Fuks, F., Vainchenker, W. The Ten-Eleven Translocation-2 (TET2) gene in hematopoiesis and hematopoietic diseases. Leukemia 28, 485-496 (2014).
6. Lian, C. G. et al. Loss of 5-hydroxymethylcytosine is an epigenetic hallmark of melanoma. Cell 150, 1135-1146 (2012).
7. Ko, M. et al. Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2. Nature 468, 839-843 (2010).
8. Yang, H. et al. Tumor development is associated with decrease of TET gene expression and 5-methylcytosine hydroxylation. Oncogene 32, 663-669 (2013).
9. Chen, C. D. et al. Molecular determinants of resistance to antiandrogen therapy. Nat. Med. 10, 33-39 (2004).
10. Wang, Q. et al. Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. Cell 138, 245-256 (2009).
11. Takayama, K., Inoue, S. Transcriptional network of androgen receptor in prostate cancer progression. Int. J. Urol. 20, 756-768 (2013).
12. Debes, J. D., Tindall, D. J. Mechanisms of androgen-refractory prostate cancer. N. Engl. J. Med. 351, 1488-1490 (2004).
13. Karantanos, T., Corn, P. G., Thompson, T. C. Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches. Oncogene 32, 5501-5511 (2013).
14. Lim, S. et al. Epigenetic regulation of cancer growth by histone demethylases. Int. J. Cancer. 127, 1991-1998 (2010).
15. Nagy, L. et al. Mechanism of the nuclear receptor molecular switch. Trends Biochem. Sci. 29, 317-324 (2004).
16. Buranapramest, M. et al. Chromatin remodeling and nuclear receptor signaling. Prog. Mol. Biol. Transl. Sci. 87, 193-234 (2009).
17. Dasgaputa, S., Lonard, D. M., O'Mally, B. W. Nuclear receptor coactivators: master regulators of human health and disease. Annu. Rev. Med. 65, 279-292 (2014).
18. Perissi, V., Jepsen, K., Glass, C. K., Rosenfeld, M. G. Deconstructing repression: evolving models of co-repressor action. Nat. Rev. Genet. 11, 109-123 (2010).
19. Banerjee, T., Chakravarti, D. A peak into the complex realm of histone phosphorylation. Mol. Cell. Biol. 31, 4858-4873 (2011).
20. Metzger, E. et al. Phosphorylation of histone H3 at threonine 11 established a novel chromatin mark for transcriptional regulation. Nat. Cell. Biol. 10, 53-60 (2008).
21. Kim, J. Y. et al. A role for WDR5 in integrating threonine 11 phosphorylation to lysine 4 methylation on histone H3 during androgen signaling and in prostate cancer. Mol. Cell 54, 613-625 (2014).
22. Kanamori-Katayama, M. et al. Unamplified cap analysis of gene expression on a single-molecule sequencer. Genome Res. 21, 1150-1159 (2011).
23. FANTOM Consortium and the RIKEN PMI and CLST (DGT). A promoterlevel mammalian expression atlas. Nature 507, 462-470 (2014).
24. Shi, X. B. et al. An androgen-regulated miRNA suppresses Bak1 expression and induces androgen-independent growth of prostate cancer cells. Proc. Natl Acad. Sci. USA 104, 19983-19988 (2007).
25. Ribas, J. et al. miR-21: an androgen receptor-regulated microRNA that promotes hormone-dependent and hormone-independent prostate cancer growth. Cancer Res. 69, 7165-7169 (2009).
26. Murata, T. et al. miR-148a is an androgen-responsive microRNA that promotes LNCaP prostate cell growth by repressing its target CAND1 expression. Prostate Cancer Prostatic Dis. 13, 356-361 (2010).
27. Hu, L. et al. Crystal structure of TET2-DNA complex: insight into TETmediated 5mC oxidation. Cell 155, 1545-1555 (2013).
28. Escamilla-Powers, J. R. et al. The tumor suppressor protein HBP1 is a novel c-myc-binding protein that negatively regulates c-myc transcriptional activity. J. Biol. Chem. 285, 4847-4858 (2010).
29. Song, C. X. et al. Selective chemical labeling reveals the genome-wide distribution of 5-hydroxymethylcytosine. Nat. Biotechnol. 29, 68-72 (2010).
30. Zhang, Y. et al. Model-based analysis of ChIP-Seq (MACS). Genome Biol. 9, R137 (2008).
31. Jozwik, K. M., Carroll, J. S. Pioneer factors in hormone-dependent cancers. Nat. Rev. Cancer 12, 381-385 (2012).
32. Wang, D. et al. Reprogramming transcription by distinct classes of enhancers functionally defined by eRNA. Nature 474, 390-394 (2011).
33. Tan, P. Y. et al. Integration of regulatory networks by NKX3-1 promotes androgen-dependent prostate cancer survival. Mol. Cell Biol. 32, 399-414 (2012).
34. Hsieh, A. C. et al. The translational landscape of mTOR signalling steers cancer initiation and metastasis. Nature 485, 55-61 (2012).
35. Chen, S. et al. Androgen receptor phosphorylation and stabilization in prostate cancer by cyclin-dependent kinase 1. Proc. Natl Acad. Sci. USA 103, 15969-15974 (2006).
36. Phillips, R. Prostate cancer: an enzalutamide antiandrogen withdrawal syndrome. Nat. Rev. Urol 11, 366 (2014).
37. Cao, Q. et al. Coordinated regulation of polycomb group complexes through microRNAs in cancer. Cancer Cell 20, 187-199 (2011).
38. Lu, J. et al. MicroRNA expression profiles classify human cancers. Nature 435, 834-838 (2005).
39. Croce, C. M. Causes and consequences of microRNA dysregulation in cancer. Nat. Rev. Genet. 10, 704-714 (2009).
40. Thieu, W., Tilki, D., deVere White, R. W., Evans, C. P. The role of microRNA in castration-resistant prostate cancer. Urol. Oncol. 32, 517-523 (2014).
41. Wang, Y., Zhang, X., Li, H., Yu, J., Ren, X. The role of miRNA-29 family in cancer. Eur. J. Cell Biol. 92, 123-128 (2013).
42. Jiang, H., Zhang, G., Wu, J. H., Jiang, C. P. Diverse roles of miR-29 in cancer. Oncol. Rep. 31, 1509-1516 (2014).
43. Wang, C., Bian, Z., Wei, D., Zhang, J. G. miR-29b regulates migration of human breast cancer cells. Mol. Cell. Biochem. 352, 197-207 (2011).
44. Gebeshuber, C. A., Zatloukal, K., Martinez, J. miR-29a suppresses tristetraprolin, which is a regulator of epithelial polarity and metastasis. EMBO Rep. 10, 400-405 (2009).
45. Kroon, P. et al. JAK-STAT blockade inhibits tumor initiation and clonogenic recovery of prostate cancer stem-like cells. Cancer Res. 73, 5288-5298 (2013).
46. Wang, G. et al. Crosstalk between the androgen receptor and beta-catenin in castrate-resistant prostate cancer. Cancer Res. 68, 9918-9927 (2008).
47. Burgio, S. L. et al. Perspective on mTOR inhibitors for castration-refractory prostate cancer. Curr. Cancer Drug Targets 12, 940-949 (2012).
48. Takayama, K. et al. Integration of cap analysis of gene expression and chromatin immunoprecipitation analysis on array reveals genome-wide androgen receptor signaling in prostate cancer cells. Oncogene 30, 619-630 (2011).
49. Takayama, K. et al. Androgen-responsive long noncoding RNA CTBP1-AS promotes prostate cancer. EMBO J. 32, 1665-1680 (2013).
50. Takayama, K. et al. CtBP2 modulates the androgen receptor to promote prostate cancer progression. Cancer Res. 74, 6542-6553 (2014).
51. Hagege, H. et al. Quantitative analysis of chromosome conformation capture assays (3C-qPCR). Nat. Protoc. 2, 1722-1733 (2007).
52. Takayama, K. et al. RUNX1, an androgen-and EZH2-regulated gene, has differential roles in AR-dependent and-independent prostate cancer. Oncotarget 6, 2263-2276 (2015).
53. Huang, D. W., Sherman, B. T., Lempicki, R. A. Systematic and integrative analysis of large gene lists using DAVID Bioinformatics Resources. Nat. Protoc. 4, 44-57 (2009).
54. Huang, D. W., Sherman, B. T., Lempicki, R. A. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res. 37, 1-13 (2009).
55. Heinz, S. et al. Simple combinations of lineage-determining transcription factors prime cis-regulatory elements required for macrophage and B cell identities. Mol. Cell. 38, 576-589 (2010).
56. Takayama, K. et al. Integrative analysis of FOXP1 function reveals a tumorsuppressive effect in prostate cancer. Mol. Endocrinol. 28, 2012-2024 (2014).